Misonix, Inc. (Misonix), a company focused in ultrasonic technology, has expanded for second time its direct sales channel for the US for SonicOne Wound Management System and SonaStar Ultrasonic Surgical Aspirator. The company has added five more region managers who will sell Misonix labeled product directly to hospitals and clinics. The key markets include California, Texas, New York, Florida, and Illinois. Aesculap, Inc. (Aesculap), a provider of surgical instrumentation, who previosuly sold SonaStar exclusively in the US, will continue to sell SonaStar on a non-exclusive basis.
The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
We are confident that by expanding our domestic sales organization we can grow our revenue in the United States, said Michael A. McManus, Jr., president and chief executive officer of Misonix. This sales group is designed to increase market penetration and increase revenue for these important products while building customer awareness and brand equity for Misonix. Additionally, we believe this sales team, which is very experienced in the sale of medical equipment and disposables, will provide us with the capability to effectively sell other Misonix labeled products to US clinical customers in the years to come.